Achieve and Maintain Biochemical Control
More patients with acromegaly experienced biochemical control when switched to Signifor® (pasireotide) compared to remaining on first-generation somatostatin analogs (SSAs).1-3
Greater Binding Affinity vs Octreotide and Lanreotide
Signifor® (pasireotide) has a unique mechanism of action (MOA), with a binding affinity 30-40 times greater than octreotide to sst5.1
A Commitment to Patient Care
Novartis’ Mobile Home Administration Programme (MAP) provides access to nurses specially trained to administer Signifor® (pasireotide).*
*MAP programme is not available in
DISCLAIMER: This is an international Web site for Signifor® (pasireotide) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country specific and may contain information that is outside the approved indications in the country in which you are located
Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
References: 1. Signifor Summary of Product Characteristics. Novartis Pharma AG; 2016. 2. Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. Published online September 24, 2014. http://dx.doi.org/10.1016/S2213-8587(14)70169-X. 3. Data on file. Novartis Pharmaceuticals Corporation. 4. Nolan LA, Schmid HA, Levy A. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Endocrinology. 2007;148(6):2821-2827.
Please see Summary of Product Characteristics.